We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.05%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$6.32B
AUM Growth
+$456M
(+7.8%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
17.62%
Holding
844
New
72
Increased
349
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$37.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$29.3M |
| 3 |
Biogen
BIIB
|
+$27.4M |
| 4 |
Home Depot
HD
|
+$22.7M |
| 5 |
Cisco
CSCO
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$23.6M |
| 2 |
TJX Companies
TJX
|
+$19.3M |
| 3 |
FedEx
FDX
|
+$16.4M |
| 4 |
Intuit
INTU
|
+$14.7M |
| 5 |
Corning
GLW
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Technology | 17.19% |
| 3 | Financials | 12.85% |
| 4 | Consumer Discretionary | 10.2% |
| 5 | Communication Services | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Paychex
PAYX
$40.4B
| $1.7M | 0.03% |
24,842
-365
| -1% | -$23.5K |
|
502
Rogers Communications
RCI
$17.7B
| $1.69M | 0.03% |
35,586
-7,086
| -17% | -$333K |
|
503
Larimar Therapeutics
LRMR
$416M
| $1.69M | 0.03% |
13,750
+5,833
| +74% | +$495K |
|
504
Kohl's
KSS
$2.03B
| $1.66M | 0.03% |
22,733
-2,616
| -10% | -$174K |
|
505
Steel Dynamics
STLD
$35.6B
| $1.66M | 0.03% |
36,024
+8,292
| +30% | +$392K |
|
506
FirstEnergy
FE
$28.9B
| $1.63M | 0.03% |
45,400
-189,614
| -81% | -$6.5M |
|
|
PARA
507
DELISTED
Paramount Global Class B
PARA
| $1.62M | 0.03% |
28,836
+1,602
| +6% | +$83.7K |
|
508
AutoZone
AZO
$48.3B
| $1.6M | 0.03% |
2,383
| – | – |
|
509
O'Reilly Automotive
ORLY
$72.4B
| $1.58M | 0.03% |
86,610
-247,905
| -74% | -$4.32M |
|
|
CORI
510
DELISTED
Corium International, Inc.
CORI
| $1.57M | 0.02% |
196,000
| – | – |
|
511
Dollar Tree
DLTR
$23.1B
| $1.57M | 0.02% |
18,423
+557
| +3% | +$51.4K |
|
512
Expeditors International
EXPD
$22.9B
| $1.56M | 0.02% |
21,386
-46,961
| -69% | -$3.28M |
|
513
Methanex
MEOH
$4.32B
| $1.55M | 0.02% |
21,996
+12,187
| +124% | +$817K |
|
514
Albemarle
ALB
$13.5B
| $1.55M | 0.02% |
16,395
-36,017
| -69% | -$3.46M |
|
515
Mesa Laboratories
MLAB
$539M
| $1.52M | 0.02% |
7,200
| – | – |
|
516
Entergy
ETR
$54.1B
| $1.51M | 0.02% |
37,488
+4,352
| +13% | +$172K |
|
|
RARX
517
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $1.49M | 0.02% |
150,000
-1,000
| -0.7% | -$6.91K |
|
518
Canadian Pacific Kansas City
CP
$82B
| $1.49M | 0.02% |
40,710
-5,680
| -12% | -$209K |
|
519
Clorox
CLX
$11.6B
| $1.48M | 0.02% |
10,919
+39
| +0.4% | +$4.81K |
|
|
CA
520
DELISTED
CA, Inc.
CA
| $1.47M | 0.02% |
41,312
+9,295
| +29% | +$328K |
|
521
Digital Realty Trust
DLR
$73.7B
| $1.45M | 0.02% |
13,000
-1,119
| -8% | -$119K |
|
|
S
522
DELISTED
Sprint Corporation
S
| $1.45M | 0.02% |
266,799
-193,243
| -42% | -$1.05M |
|
523
Enanta Pharmaceuticals
ENTA
$372M
| $1.45M | 0.02% |
12,500
-12,000
| -49% | -$1.2M |
|
524
Delta Air Lines
DAL
$55.9B
| $1.45M | 0.02% |
29,223
-116,685
| -80% | -$6.22M |
|
525
Ventas
VTR
$48.9B
| $1.45M | 0.02% |
25,374
-133
| -0.5% | -$6.96K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2018 Portfolio in Review
As of Q2 2018, Candriam SCA held 844 positions worth $6.32B, up 7.8% from $5.86B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Candriam SCA deployed $224M of net new capital in Q2 2018, opening 72 new positions and adding to 349 existing holdings. Its largest new stake was Broadcom: 1,532,450 shares worth $37.2M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was JPMorgan Chase, an estimated $23.6M trimmed.
- Candriam SCA's largest Q2 2018 buy was Broadcom: 1,532,450 shares worth $37.2M.
- Candriam SCA added most to Bristol-Myers Squibb in Q2 2018, an estimated $29.3M increase.
- Candriam SCA's biggest Q2 2018 reduction was JPMorgan Chase, cutting an estimated $23.6M.
- Candriam SCA fully exited Monsanto Co in Q2 2018, selling an estimated $11.5M.
- Candriam SCA's ten largest holdings make up 18% of its $6.32B portfolio in Q2 2018.
- Candriam SCA opened 72 new positions and closed 60 in Q2 2018.
- Candriam SCA's portfolio value rose 7.8% quarter-over-quarter to $6.32B.
Based on Candriam SCA's 13F filing for Q2 2018, filed 14 Aug 2018.